Phase 3 Alzheimer Clinical Trials
46 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 46 trials
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled148 locationsNCT06159673
Recruiting
Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Alzheimers Disease
Hoffmann-La Roche80,000 enrolled211 locationsNCT07177352
Recruiting
Phase 3
An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
Alzheimer's Disease (AD)Mild Cognitive Impairment Due to Alzheimer's DiseaseAlzheimer Disease Dementia
University College, London1,200 enrolled2 locationsNCT07724132
Recruiting
Phase 3
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
Alzheimer Disease
Eli Lilly and Company140 enrolled30 locationsNCT07571161
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled126 locationsNCT06976203
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled129 locationsNCT05511363
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb426 enrolled158 locationsNCT07011732
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
DementiaAlzheimer DiseasePlaque, Amyloid
Eli Lilly and Company550 enrolled59 locationsNCT07602582
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 enrolled292 locationsNCT06585787
Recruiting
Phase 3
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers Disease
Hoffmann-La Roche800 enrolled150 locationsNCT07170150
Recruiting
Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
Alzheimer Disease
Eli Lilly and Company3,400 enrolled4 locationsNCT07142954
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company1,000 enrolled429 locationsNCT05980949
Recruiting
Phase 3
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers Disease
Hoffmann-La Roche800 enrolled143 locationsNCT07169578
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb650 enrolled256 locationsNCT06937229
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled22 locationsNCT06947941
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled116 locationsNCT06976216
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled145 locationsNCT07011745
Recruiting
Phase 2Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled49 locationsNCT07284472
Recruiting
Phase 3
[18F]PI-2620 Phase 3 Histopathological Study
Alzheimer Disease
Lantheus Biosciences Ltd.200 enrolled25 locationsNCT05641688